Posted by Michael Wonder on 24 Jun 2025
Ozempic receives EU recommendation in peripheral arterial disease, cementing the broad benefits of semaglutide for people with type 2 diabetes and co-morbidities
23 June 2025 - Pending a decision from the European Commission, Ozempic (once weekly semaglutide) will have the broadest approved label in the glucagon-like peptide-1 receptor agonist class, demonstrating improvements in blood sugar, weight, cardiovascular events, chronic kidney disease and peripheral arterial disease functional outcomes.
Novo Nordisk today announced that the EMA's CHMP has adopted a positive opinion for an update of the Ozempic (once weekly semaglutide) label to reflect the positive data from the STRIDE peripheral artery disease functional outcomes trial.
